Pfizer Company Profile

What is the competitive landscape for PFIZER

PFIZER has one hundred and ninety-seven approved drugs.

There are fifty US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

Summary for Pfizer

US Patents:	50
Tradenames:	161
Ingredients:	131
NDAs:	197
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Drugs and US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PFIZERPEN VK	penicillin v potassium	FOR SOLUTION;ORAL	061815-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-002	Oct 1, 1997		DISCN	No	No
Pfizer	DAYPRO ALTA	oxaprozin potassium	TABLET;ORAL	020776-001	Oct 17, 2002		DISCN	No	No
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	10,723,730*PED				Y
Pfizer	VIBRAMYCIN	doxycycline hyclate	INJECTABLE;INJECTION	050442-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	DEPO-PROVERA	medroxyprogesterone acetate	INJECTABLE;INJECTION	012541-003	Approved Prior to Jan 1, 1982	4,038,389
Pfizer Pharms	LOPID	gemfibrozil	CAPSULE;ORAL	018422-002	Approved Prior to Jan 1, 1982	3,674,836
Pfizer	COVERA-HS	verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020552-001	Feb 26, 1996	4,946,687
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019	7,456,168
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997	5,763,454

Paragraph IV (Patent) Challenges for PFIZER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	4 mg and 8 mg		2012-10-31
	Injection	20 mg/mL, 2 mL and 5 mL vials		2004-07-26
	Capsules	5 mg and 10 mg		2005-06-21
	For Injection	500 mg/vial		2011-06-17
	Oral Suspension	100 mg/5 mL		2009-08-03
	Injection	2 mg/mL, 100 mL bag		2009-12-29
	Tablets	5 mg		2016-11-07
	Delayed-release Tablets	50 mg/0.2 mg		2009-06-29
	Extended-release Tablets	11 mg		2016-11-07
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Capsules	75 mg, 100 mg and 125 mg		2019-02-04
	Capsules	0.125 mg, 0.25 mg, and 0.5 mg		2014-05-01
	Tablets	600 mg		2005-12-21
	Injection	2 mg/mL, 300 mL bag		2009-09-01
	Tablets	1 g		2005-08-23
	Delayed-release Tablets	75 mg/0.2 mg		2008-11-28

International Patents for Pfizer Drugs

Country	Patent Number	Estimated Expiration
Mexico	354134
Eurasian Patent Organization	201270751
South Korea	20180022936
European Patent Office	4166539
Canada	2596714

Supplementary Protection Certificates for Pfizer Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2767537	132019000000153	Italy		PRODUCT NAME: TALAZOPARIB(TALZENNA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1377, 20190624
2767537	C02767537/01	Switzerland		FORMER OWNER: MEDIVATION TECHNOLOGIES LLC, US
2326621	2024C/532	Belgium		PRODUCT NAME: ETRASIMOD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS ETRASIMOD ARGININE; AUTHORISATION NUMBER AND DATE: EU/1/23/1790 20240219
2170860	C20200032 00354	Estonia		PRODUCT NAME: GLASDEGIIB;REG NO/DATE: EU/1/20/1451 29.06.2020
1304992	2013C/060	Belgium		PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pfizer
• Pfizer Global
• Pfizer Inc
• Pfizer Labs
• Pfizer Pharms